• 
• 
• 
• 
• 
• 

The BioMarin Morquio A (MPS IVA) Program

BioMarin is currently investigating a potential treatment to benefit patients diagnosed with mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome. BioMarin’s initial development plans include two studies: MorCAP (a clinical assessment program) and a Phase 1/2 clinical trial.

BioMarin has successfully developed 2 FDA-approved enzyme replacement therapy treatments for MPS: for MPS I and MPS VI. We now look forward to extending our experience and expertise to address the therapeutic needs of the Morquio A patient.